The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.

Kohei Shitara,Mustafa Ozguroglu,Yung-Jue Bang,Maria Di Bartolomeo,Mario Mandalà,Min-Hee Ryu,Caterina Vivaldi,Tomasz Olesiński,Hyun Cheol Chung,Kei Muro,Eric Van Cutsem,J Kobie,Razvan Cristescu,D Aurora-Garg,Jia Lu,Chie-Schin Shih,David Adelberg,Z. Alexander Cao,David Fabrizio,Charles S. Fuchs

The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.

2020

4537Background: KEYNOTE-061 (NCT02370498) was a randomized, open-label, phase 3 study of pembrolizumab vs paclitaxel in pts with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma w...

Keywords:

Cancer
Oncology
Internal medicine
Paclitaxel
Pathology
Pembrolizumab
in patient
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations